130 related articles for article (PubMed ID: 14522350)
21. Treatment of subdiaphragmatic Hodgkin's disease: long-term results and side effects.
Cutuli B; Petit T; Hoffstetter S; Velten M; Dufour P; Giron C; Lederlin P; Jung GM; Bergerat JP; Maloisel F; Bey P; Oberling F
Oncol Rep; 1998; 5(6):1513-8. PubMed ID: 9769397
[TBL] [Abstract][Full Text] [Related]
22. Second cancer among long-term survivors from Hodgkin's disease.
Nyandoto P; Muhonen T; Joensuu H
Int J Radiat Oncol Biol Phys; 1998 Sep; 42(2):373-8. PubMed ID: 9788418
[TBL] [Abstract][Full Text] [Related]
23. Survival in Hodgkin's disease patients--report of 25 years of experience at the Milan Cancer Institute.
Bonadonna G; Viviani S; Bonfante V; Gianni AM; Valagussa P
Eur J Cancer; 2005 May; 41(7):998-1006. PubMed ID: 15862748
[TBL] [Abstract][Full Text] [Related]
24. A randomized study in stage IIIB and IV Hodgkin's disease comparing eight courses of MOPP versus an alteration of MOPP with ABVD: a European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group and Groupe Pierre-et-Marie-Curie controlled clinical trial.
Somers R; Carde P; Henry-Amar M; Tarayre M; Thomas J; Hagenbeek A; Monconduit M; de Pauw BE; Breed WP; Verdonck L
J Clin Oncol; 1994 Feb; 12(2):279-87. PubMed ID: 7509381
[TBL] [Abstract][Full Text] [Related]
25. Combined modality therapy for advanced Hodgkin's disease: 15-year follow-up data.
Prosnitz LR; Farber LR; Kapp DS; Scott J; Bertino JR; Fischer JJ; Cadman EC
J Clin Oncol; 1988 Apr; 6(4):603-12. PubMed ID: 2451712
[TBL] [Abstract][Full Text] [Related]
26. Salvage chemotherapy in Hodgkin's disease irradiation failures: superiority of doxorubicin-containing regimens over MOPP.
Santoro A; Viviani S; Villarreal CJ; Bonfante V; Delfino A; Valagussa P; Bonadonna G
Cancer Treat Rep; 1986 Mar; 70(3):343-8. PubMed ID: 2420444
[TBL] [Abstract][Full Text] [Related]
27. Is ABVD the standard regimen for Hodgkin's disease based on randomized CALGB comparison of MOPP, ABVD and MOPP alternating with ABVD?
Canellos GP
Leukemia; 1996 Jun; 10 Suppl 2():s68. PubMed ID: 8649055
[No Abstract] [Full Text] [Related]
28. MOPPEBVCAD chemotherapy with limited and conditioned radiotherapy in advanced Hodgkin's lymphoma: 10-year results, late toxicity, and second tumors.
Gobbi PG; Broglia C; Levis A; La Sala A; Valentino F; Chisesi T; Sacchi S; Corbella F; Cavanna L; Iannitto E; Pavone V; Molica S; Corazza GR; Federico M
Clin Cancer Res; 2006 Jan; 12(2):529-35. PubMed ID: 16428496
[TBL] [Abstract][Full Text] [Related]
29. Hybrid chemotherapy consisting of cyclophosphamide, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, and vinblastine (C-MOPP/ABV) as first-line treatment for patients with advanced Hodgkin disease.
Montoto S; Camós M; López-Guillermo A; Bosch F; Cervantes F; Blandé J; Esteve J; Cobo F; Nomdedeu B; Campo E; Montserrat E
Cancer; 2000 May; 88(9):2142-8. PubMed ID: 10813727
[TBL] [Abstract][Full Text] [Related]
30. Low risk of secondary leukemias after chemotherapy without mechlorethamine in childhood Hodgkin's disease. German-Austrian Pediatric Hodgkin's Disease Group.
Schellong G; Riepenhausen M; Creutzig U; Ritter J; Harbott J; Mann G; Gadner H
J Clin Oncol; 1997 Jun; 15(6):2247-53. PubMed ID: 9196137
[TBL] [Abstract][Full Text] [Related]
31. Long-term pulmonary sequelae after treatment of childhood Hodgkin's disease.
Bossi G; Cerveri I; Volpini E; Corsico A; Baio A; Corbella F; Klersy C; Arico M
Ann Oncol; 1997; 8 Suppl 1():19-24. PubMed ID: 9187424
[TBL] [Abstract][Full Text] [Related]
32. Long-term follow-up analysis of HD9601 trial comparing ABVD versus Stanford V versus MOPP/EBV/CAD in patients with newly diagnosed advanced-stage Hodgkin's lymphoma: a study from the Intergruppo Italiano Linfomi.
Chisesi T; Bellei M; Luminari S; Montanini A; Marcheselli L; Levis A; Gobbi P; Vitolo U; Stelitano C; Pavone V; Merli F; Liberati M; Baldini L; Bordonaro R; Pesce EA; Federico M
J Clin Oncol; 2011 Nov; 29(32):4227-33. PubMed ID: 21990405
[TBL] [Abstract][Full Text] [Related]
33. Alternating versus hybrid MOPP and ABVD combinations in advanced Hodgkin's disease: ten-year results.
Viviani S; Bonadonna G; Santoro A; Bonfante V; Zanini M; Devizzi L; Soncini F; Valagussa P
J Clin Oncol; 1996 May; 14(5):1421-30. PubMed ID: 8622055
[TBL] [Abstract][Full Text] [Related]
34. Treatment of advanced Hodgkin's disease with chemotherapy--comparison of MOPP/ABV hybrid regimen with alternating courses of MOPP and ABVD: a report from the National Cancer Institute of Canada clinical trials group.
Connors JM; Klimo P; Adams G; Burns BF; Cooper I; Meyer RM; O'Reilly SE; Pater J; Quirt I; Sadura A; Shustik C; Skillings J; Sutcliffe S; Verma S; Yoshida S; Zee B
J Clin Oncol; 1997 Apr; 15(4):1638-45. PubMed ID: 9193364
[TBL] [Abstract][Full Text] [Related]
35. Assessment of cardiac and pulmonary function in adult patients with Hodgkin's disease treated with ABVD or MOPP/ABVD plus adjuvant low-dose mediastinal irradiation.
Salloum E; Tanoue LT; Wackers FJ; Zelterman D; Hu GL; Cooper DL
Cancer Invest; 1999; 17(3):171-80. PubMed ID: 10099655
[TBL] [Abstract][Full Text] [Related]
36. The risk of acute leukemia in patients treated for Hodgkin's disease is significantly higher aft [see bined modality programs than after chemotherapy alone and is correlated with the extent of radiotherapy and type and duration of chemotherapy: a case-control study.
Brusamolino E; Anselmo AP; Klersy C; Santoro M; Orlandi E; Pagnucco G; Lunghi F; Maurizi-Enrici R; Baroni CD; Lazzarino M; Mandelli F; Bernasconi C
Haematologica; 1998 Sep; 83(9):812-23. PubMed ID: 9825578
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and toxicity of 12 courses of ABVD chemotherapy followed by low-dose regional radiation in advanced Hodgkin's disease in children: a report from the Children's Cancer Study Group.
Fryer CJ; Hutchinson RJ; Krailo M; Collins RD; Constine LS; Hays DM; Heller RM; Davis PC; Nachman J; O'Brien RT
J Clin Oncol; 1990 Dec; 8(12):1971-80. PubMed ID: 1700080
[TBL] [Abstract][Full Text] [Related]
38. [Combined-modality therapy for 150 cases of early-stage Hodgkin's lymphoma].
Niu Y; Shi YK; He XH; Feng FY; Zhou LQ; Gu DZ
Zhonghua Zhong Liu Za Zhi; 2008 Aug; 30(8):630-4. PubMed ID: 19102946
[TBL] [Abstract][Full Text] [Related]
39. Can MOPP be replaced in the treatment of advanced Hodgkin's disease?
Canellos GP
Semin Oncol; 1990 Feb; 17(1 Suppl 2):2-6. PubMed ID: 1689509
[TBL] [Abstract][Full Text] [Related]
40. Radiotherapy alone for lymphocyte-predominant Hodgkin's disease.
Schlembach PJ; Wilder RB; Jones D; Ha CS; Fayad LE; Younes A; Hagemeister F; Hess M; Cabanillas F; Cox JD
Cancer J; 2002; 8(5):377-83. PubMed ID: 12416895
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
